About this Research Topic
Thrombosis is the dominant process in several cardiovascular diseases—such as acute coronary syndromes, deep vein thrombosis and pulmonary embolism, and ischemic stroke—remaining major causes of morbidity and mortality worldwide when not properly managed.
The prevention and treatment of thrombosis-related diseases primarily involve the use of antiplatelet agents and anticoagulants as the therapies of choice. However, despite their undoubted benefits and advantages, these therapies carry significant risks, with bleeding being a major side effect.
Antiplatelet agents and anticoagulants represent the first-line therapy for the prevention and treatment of thrombosis-related diseases. However, despite their undisputed benefits, they have many risks, and bleeding remains a major side effect. New concepts and drugs have been studied, leading to the development of novel direct oral anticoagulants (DOACs) and antiplatelet agents (such as P2Y12 inhibitors and GIIb/IIIa inhibitors), which represent significant advances in antithrombotic therapy. Although DOACs attenuate thrombosis without significantly perturbing hemostasis—a new goal in anticoagulant therapy—they also present the risk of bleeding similar to classical anticoagulants. In this context, research focuses on new active compounds targeting FXIIa or FXIa. These strategies are expected to greatly impact patients’ quality of life and prolong their life expectancy.
Authors are encouraged to submit papers focusing on recent advances, current challenges, and future perspectives of antithrombotic agents.
We are particularly interested in topics that include, but are not limited to:
-Pathophysiological and pharmacological mechanisms
-Clinical evaluation of antithrombotic drugs
-Chemical modulation of antithrombotic drugs
Cardiovascular and Smooth Muscle Pharmacology welcomes submissions of the following article types: Brief Research Report, Case Report, Correction, Editorial, General Commentary, Hypothesis & Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Review, Technology, and Code.
The prevention and treatment of thrombosis-related diseases primarily involve the use of antiplatelet agents and anticoagulants as the therapies of choice. However, despite their undoubted benefits and advantages, these therapies carry significant risks, with bleeding being a major side effect.
Antiplatelet agents and anticoagulants represent the first-line therapy for the prevention and treatment of thrombosis-related diseases. However, despite their undisputed benefits, they have many risks, and bleeding remains a major side effect. New concepts and drugs have been studied, leading to the development of novel direct oral anticoagulants (DOACs) and antiplatelet agents (such as P2Y12 inhibitors and GIIb/IIIa inhibitors), which represent significant advances in antithrombotic therapy. Although DOACs attenuate thrombosis without significantly perturbing hemostasis—a new goal in anticoagulant therapy—they also present the risk of bleeding similar to classical anticoagulants. In this context, research focuses on new active compounds targeting FXIIa or FXIa. These strategies are expected to greatly impact patients’ quality of life and prolong their life expectancy.
Authors are encouraged to submit papers focusing on recent advances, current challenges, and future perspectives of antithrombotic agents.
We are particularly interested in topics that include, but are not limited to:
-Pathophysiological and pharmacological mechanisms
-Clinical evaluation of antithrombotic drugs
-Chemical modulation of antithrombotic drugs
Cardiovascular and Smooth Muscle Pharmacology welcomes submissions of the following article types: Brief Research Report, Case Report, Correction, Editorial, General Commentary, Hypothesis & Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Review, Technology, and Code.
Keywords: thrombosis, coagulation cascade, platelet aggregation, antithrombotics, antiplatelets agents, anticoagulants, pathophysiology of thrombosis, pharmacology of antithrombotics, adverse reactions, structure–activity relationships
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
